Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified

Sanofi acquires rights to develop and commercialize Aficamten in Greater China

In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China

Sanofi invests €40 million to strengthen antibody bioproduction in France

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

Panacea Biotec and Sanofi reached settlement agreement for Shan6

Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351

Sanofi Consumer Healthcare India appoints Himanshu Bakshi as MD

Himanshu brings with him a wealth of rich experience from commercial, marketing, and general management roles

Lupin completes acquisition of two brands from Sanofi in Europe and Canada

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas

Bluecrux supports Sanofi in harnessing AI to transform supply chains

Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024